

1 **SARS-CoV-2 Infection Breakthrough among the non-vaccinated and vaccinated: a Real**
2 **World Evidence study based on Big Data**

3 Perrella A^{*1,6}, Bisogno M³, D'Argenzio^{1,2}, Trama U^{1,2}, Coscioni E^{1,4}, Orlando V^{*2,5}
4 and COVID CaRe group

5 ¹ Regional Task Force COVID-19, Campania Region, Naples, Italy;

6 ² Directorate-General for Health Protection, Campania Region, Naples, Italy;

7 ³ Sinfonia Regional Health Information System of Campania Region, Naples, Italy;

8 ⁴ Division of Cardiac Surgery, AOU San Giovanni di Dio e Ruggi d'Aragona, Salerno, Italy;

9 ⁵ CIRFF (Center of Drug Utilization and Pharmacoeconomics), Department of Pharmacy, University of Naples
10 Federico II, Naples, Italy;

11 ⁶ Hospital Health Direction, Infectious Disease Unit, Hospital A. Cardarelli, Naples, Italy

12 *Correspondence:

13 Valentina Orlando, email: valentina.orlando@unina.it;

14 Alessandro Perrella, email: alessandro.perrella@occardarelli.it

15 **Ethical Committee Waived:** Prot.N. 00000926 - 11/01/2022

16 **Collaborative Authors**

17 The list of collaborators of the group and their affiliation are the following:

18 **The COVID CaRe Group**

19 Italo Giulivo¹, Antonio Postiglione^{1,2}, Claudia Campobasso¹, Giuseppe Galano¹, Maurizio Di
20 Mauro¹, Enrico Coscioni^{1,5}, Alessandro Perrella^{1,6}, Angelo D'Argenzio^{1,2}, Ugo Trama^{1, 2}, Maria
21 Rosaria Romano^{1, 2}, Giuseppina Tommasielli¹, Ciro Verdoliva¹, Antonio D'Amore¹, Gennaro
22 Sosto¹, Ferdinando Russo¹, Maria Morgante¹, Gennaro Volpe¹, Mario Iervolino¹, Carlo Marino¹,
23 Paolo Russo¹, Roberta Santaniello¹, Michele Cioffi¹, Guido Maria Talarico¹, Giuseppe Longo¹,
24 Mario Nicola Vittorio Ferrante¹, Anna Iervolino¹, Antonio Giordano¹, Renato Pizzuti¹, Vincenzo
25 D'Amato¹, Antonio Limone¹, Antonio Corcione¹, Francesco Diurno¹, Gaetano Gubitosa¹, Pietro
26 Buono², Massimo Bisogno³, Valerio Morfino³, Valentina Orlando^{2,4}, Enrica Menditto⁴, Ilaria
27 Guarino⁴, Francesca Futura Bernardi², Giovanna Affinito², Massimo Majolo⁶, Novella
28 Carannante².

29 ¹ Regional crisis Unit COVID-19, Campania Region, Naples, Italy;

30 ² Directorate-General for Health Protection, Campania Region, Naples, Italy;

31 ³ Sinfonia Regional Health Information System of Campania Region, Naples, Italy

32 ⁴ CIRFF (Center of Drug Utilization and Pharmacoeconomics) , Department of Pharmacy, University of Naples
33 Federico II, Naples, Italy;

34 ⁵ Division of Cardiac Surgery, AOU San Giovanni di Dio e Ruggi d'Aragona, Salerno, Italy;

35 ⁶ Hospital Health Direction, Infectious Disease Unit, Hospital A. Cardarelli, Naples, Italy

36 **ABSTRACT**

37 **Background:**

38 SARS-CoV-2 infection after vaccination can occur because COVID-19 vaccines do not offer 100%
39 protection. The aim of this study was to assess vaccination coverage among people nasopharyngeal
40 swabs, disease symptoms and type of hospitalisation (Intensive Care Unit) between the non-
41 vaccinated and the effective dose vaccinated and to evaluate vaccination trend over time.

42 **Methods:**

43 A retrospective cohort study was carried out among people tested positive for COVID-19 in
44 Campania Region using collected information from Health Information System of Campania
45 Region (Sinfonia).

46 The status of vaccination was assess according to the following timetable: “non-vaccinated”;
47 “Ineffective dose” vaccination; “Effective dose” vaccination.

48 Univariate and multivariate logistic regression models were conducted to evaluate the association
49 between Intensive Care Unit (ICU) to COVID-19 and gender, age groups and vaccine.

50 To determine vaccine coverage in subjects who received an effective dose, trend changes over time
51 were investigated using segmented linear regression models and breakpoints estimations.

52 Vaccination coverage was assessed by analysing the trend in the percentage of covid 19 positive
53 subjects in the 9 months after vaccination with an effective dose stratified by age group and type of
54 vaccine. Statistical analyses were performed using R platform

55 **Results:**

56 A significant association with the risk of hospitalisation in Intensive Care Unit was the vaccination
57 status of the subjects: subjects with ineffective dose (adjusted OR: 3.68) and subjects no-
58 vaccination (adjusted OR: 7.14) were at three- and seven-times higher risk of hospitalisation in
59 Intensive Care Unit, respectively, than subjects with an effective dose.

60 Regarding subjects with an effective dose of vaccine, the vaccine's ability to protect against
61 infection in the months following vaccination decreased.

62 The first breakpoints is evident five months after vaccination ($\beta = 1.441$, $p < 0.001$). This increase
63 was most evident after the seventh month after vaccination ($\beta = 3.110$, $p < 0.001$).

64 **Conclusions:**

65 COVID19 vaccines protect from symptomatic infection by significantly reducing the risk of ICU
66 hospitalization for severe disease. However, it seems they have trend to decrease their fully
67 protection against SARS-COV-2 after five months regardless age, sex or type of vaccine. Therefore
68 it seems clear that those not undergoing vaccine had higher risk to develop clinically significant
69 disease and being at risk of ICU stay. Thus, considering highest percentage of asymptomatic

70 patients and that few data about their capacity to transmit SARS-CoV-2, third dose vaccination
71 should be introduced as soon as possible while awaiting antivirals. Finally, a surveillance approach
72 based on the use of integrated BIG Data system to match all clinical conditions too, offer a precise
73 and real analysis with low incidence of errors in the categorization of subjects.

74 **Keywords:** COVID-19, vaccination coverage, Real World Evidence study, Big Data, Machine
75 Learning, SARS-COV-2, Vaccine.

76 **Introduction**

77 Since WHO declared the emergence of coronavirus disease 2019 (COVID-19) pandemic on March
78 11, 2020, over 5 million people have died worldwide, including over 130,000 people in Italy.¹

79 Due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection impact on health
80 system of all countries, some countries or pharmaceutical companies have promoted research
81 protocol to find a cure or to develop a vaccine against the SARS-CoV-2.²⁻⁴

82 Currently several vaccines have been produced and authorized, being based on different
83 technologies. In Italy at the end of 2020 and throughout 2021, following European Medical Agency
84 (EMA), Italian Medicines and Healthcare products Regulatory Agency (AIFA) authorized the
85 BNT162b2 mRNA (Pfizer-BioNTech) and ChAdOx1 nCoV-19 adenoviral (Oxford-AstraZeneca),
86 CX-024414 mRNA (Moderna) and Ad26.COV2-S Adenoviral (J&J). Since the authorization of
87 vaccine, thanks to extraordinary effort of all Italian healthcare workers and sense of civil
88 responsibility of Italian population a high percentage of people were vaccinated and COVID19
89 contagious progressively decrease over the entire country during the first 8 months of 2021.⁵

90 Despite recent studies⁶⁻⁸ there is still a lack of studies on vaccine efficacy based on real world data.

91 The aim of this study was to assess vaccination coverage among people nasopharyngeal swabs,
92 disease symptoms and type of hospitalisation (Intensive Care Unit) between the non-vaccinated and
93 the effective dose vaccinated and to evaluate vaccination trend over time.

94 **Materials and Methods**

95 **Data sources: Sinfonia**

96 Sinfonia includes records on patient demographics and for ~ 6 million residents, comprising a well-
97 defined population in Italy (~ 10% of the population of Italy).

98 Sinfonia collects information, encrypted and anonymized from Local Health Unit (LHU) whose are
99 legal owner of the original data, in accordance with the privacy laws. All analyses on the data are
100 therefore carried out on encrypted and anonymized data using transparent data encryption protocols.

101 It is complete and involves data management system that has been validated in previous studies.⁹⁻¹²

102 During the pandemic emergency, the Regional Health Information System of Campania Region
103 (Sinfonia) was implemented with all records related to COVID-19 in order to create a tool to
104 support health governance in managing the COVID-19 emergency.

105 The aims of Sinfonia tool, based on previous experiences too¹³, were:

- 106 1) Applying data science methods to big data in order to assess pandemic trends
- 107 2) Creation of predictive algorithms through AI methods
- 108 3) ML analysis, performed according to the python scripting model (Spyder IDE 64bit ver), to
109 perform predictive analysis on contagiousness.

110 The characteristics of Sinfonia are described in Supplementary Material 1

111 **Study design and cohort selection**

112 A retrospective cohort study was carried out among people tested positive for COVID-19 in
113 Campania Region since March 8, 2021, until 31 October 2021 using collected information from
114 Health Information System of Campania Region (Sinfonia).

115 Nasopharyngeal swabs were collected by trained personnel of Regional Healthcare system and/or
116 authorized and trained territorial laboratory staff. RT-PCR testing was performed with the use of
117 standardized RT-PCR machine from Coronavirus Network Laboratory (CoroNetLab), with four
118 genes analysis RdRP, S and N genes specific to SARS-CoV-2, and the E gene with results
119 expressed as the cycle threshold (Ct). A Ct value of less than 30, which indicated an increased viral
120 load, was used to determine infectivity.^{14,15}

121 Were considered as fully positive only results when all 4 genes found to be amplified by Rt-PCR
122 while in all other case results were considered doubt and repeated.^{14,15} Participant consent was
123 given for the release of all SARS-CoV-2 PCR test results before or after vaccination. All positive
124 participants were followed-up until negative PCR test.

125 For all individuals being positive at nasal swab clinical symptoms were collected according to
126 Italian National Health Institute. Typical COVID-19 symptoms were fever, cough, or change or loss
127 of taste or smell. Participants were recorded as having other symptoms if they reported any of the

128 following: shortness of breath, sore throat, runny nose, headache, muscle aches, extreme fatigue,
129 diarrhoea, nausea or vomiting, or small itchy red patches on fingers or toes, on the follow-up
130 questionnaire with a symptom onset date within 14 days before or after the PCR positive sample
131 date.

132 Data extraction was conducted from Sinfonia every month to have a regular report of
133 vaccine/positive trend and for final analysis on October 31, 2021. All collected data after ML
134 algorithm were anonymized and encrypted according to transparent data encryption.

135 Briefly, AI based on ML algorithm, was used in data mining on Sinfonia to daily match records
136 from SARS-COV-2 RT-PCR nasal swab and status of vaccination according to the following
137 timetable:

- 138 i) Positive without vaccinated being considered “*non-vaccinated*”
- 139 ii) positive after 1st dose vaccine (<15 or >15 days) or after two dose vaccine < 15 days and
140 being considered “*Ineffective dose*” vaccination,
- 141 iii) positive after two dose with more than 15 days since second dose of BNT162b2 mRNA
142 (Pfizer-BioNTech), ChAdOx1 nCoV-19 adenoviral (AstraZeneca) and CX-024414 mRNA
143 (Moderna) or in case of Ad26.COV2-S Adenoviral (J&J) 60 days after one shot and being
144 considered “*Effective dose*” vaccination.

145 Flow chart is illustrated in Figure 1.

146 All subjects provided written informed consent to vaccination and data storage on a Big Data
147 system management to collect all COVID-19 patients’ data and related clinical history (Symptoms,
148 hospital admission and related follow-up, previous clinical status) according to European Privacy
149 Policy to manage pandemic.

150 Time elapsed from second dose and onset of COVID-19 was calculated for all individuals to
151 evaluate risk of infection in time dependent way. Further, once recognized a positive subject among
152 those vaccinated was evaluated according to days elapsed since vaccine.

153 **Outcomes**

154 The primary outcome was to assess the risk of intensive care unit (ICU) admission for COVID-19
155 between the non-vaccinated and the effective dose vaccinated.

156 Secondary outcome was to evaluate vaccination coverage, over time, stratified by age group and
157 vaccine type

158 **Statistical analysis**

159 The study population baseline characteristics were analyzed using descriptive statistics.
160 Quantitative variables were described as counts and percentages. The chi-square test and t-test were
161 performed to determine the difference between non-vaccinated and vaccinated subjects who tested

162 positive for COVID-19. In particular, the vaccinated subjects were distinguished into two groups:
163 vaccinated with an ineffective dose (one vaccine dose or two vaccine doses) and vaccinated with an
164 effective dose (two vaccine doses plus 15 days: BNT162b2 mRNA (Pfizer-BioNTech), ChAdOx1
165 nCoV-19 adenoviral (AstraZeneca) and CX-024414 mRNA (Moderna); one vaccine dose plus 60
166 days: Ad26.COV2-S Adenoviral (J&J)).

167 Univariate and multivariate logistic regression models were conducted to evaluate the association
168 between Intensive Care Unit (ICU) to COVID-19 and gender, age groups (ie, 40 - 59 years, 60 - 79
169 years, ≥ 80 years vs 0-39 years) and vaccine (Non-vaccination, Ineffective dose vs Effective dose).

170 To determine vaccine coverage in subjects who received an effective dose, trend changes over time
171 were investigated using segmented linear regression models and breakpoints estimations.

172 Breakpoints were identified testing differences in slope and intercepts of the trend and then different
173 linear models were implemented. Changes in the slope segment indicated an impact of vaccination
174 coverage on protection against COVID-19 infection.

175 Every linear model was expressed as follows: $y_t = a + b * t + \epsilon_t$, where a was the intercept, b the
176 slope and ϵ_t the error term. Coefficients (β) were considered statistically significant with a P value <
177 0.05. The 95% confidence intervals (CIs) for each breakpoint were also obtained.

178 In addition, vaccination coverage was assessed by analysing the trend in the percentage of covid 19
179 positive subjects in the 9 months after vaccination with an effective dose stratified by age group and
180 type of vaccine. Statistical analyses were performed using R platform (version 3.6, The R
181 Formulation for Statistical Computing, Vienna, Austria).

182 **Results**

183 During analysed period 8 March 2021 to 31 October 2021, in Campania Region, 2,555,678 nasal
184 swabs were performed in subjects aged 18-98 years. Are showed in figure 1 of the total cohort of
185 COVID-19 positive subjects, 85.2% were non-vaccinated (N= 146.529) and 14.8% (N= 25.392)
186 were vaccinated. Of the 25,392 subjects who received at least one dose of vaccine, 7.5% (N=
187 12,906) received an ineffective dose; in comparison 7.3% (N=12,486) received an effective dose.
188 Of the total 171,921 COVID-19 positive subjects, 51.2% were females.

189 The analysis stratified by age group showed that among the total cohort of COVID-19 positive
190 subjects, 50.9% were aged 0 -39 years, 29.4% 40 - 59 years, 16.3% 60 - 79 years and 3.4% were
191 aged more than 80 years.

192 Information of disease symptoms was not available for 34,119 subjects (19.8%) included in the
193 analysis.

194 In particular, the percentage of subjects with severe and critical COVID-19 decreased in the cohort
195 of vaccinated subjects compared to non-vaccinated subjects. Among a total of 482 subjects with
196 severe symptoms 89.4% of the subjects are non-vaccinated, 7.5% of the subjects are vaccinated
197 with a non-effective dose and 3.1% of the subjects are vaccinated with an effective dose.

198 Similarly, out of 57 subjects with critical symptoms 82.5% of the subjects are non-vaccinated,
199 10.5% of the subjects are vaccinated with a non-effective dose and 7.0% of the subjects are
200 vaccinated with an effective dose.

201 Overall, 2.7% of the COVID-19 positive subjects were hospitalised and 0.1% were in intensive care
202 unit.

203 Among hospitalised subjects the majority (83.7%) were non-vaccinated, 10.3% received a non-
204 effective dose and 6.0%) received an effective dose.

205 Among subjects in Intensive Care Unit (ICU) the majority (90.5%) were non-vaccinated, 7.6%
206 received a non-effective dose and 1.9% received an effective dose (Table 1).

207 Table 2 reports the results of the univariate and multivariate logistic regression analyses, which
208 showed that three independent variables made a statistically significant contribution to the model:
209 gender, age, and vaccination status of the subjects were the main determinants of the risk of
210 hospitalisation in Intensive Care Unit (ICU) to COVID-19.

211 A significant association with the risk of hospitalisation in Intensive Care Unit was the gender.
212 Males (adjusted odds ratio [OR]: 1.70; 95% CI: 1.29 - 2.24, p value <0.001) were at almost two
213 times higher risk of hospitalization in Intensive Care Unit than females. Similarly, a strong
214 significant association with the risk of hospitalisation in Intensive Care Unit was the age. Subjects
215 aged 60-79 years (adjusted odds ratio [OR]: 33.53; 95% CI: 19.31–58.23, p value <0.001) and

216 subjects aged more than 80 years (adjusted odds ratio [OR]: 29.04; 95% CI: 14.48 - 58.27, p value
217 <0.001) were more than thirty times and twenty-nine times, respectively, likely to the risk of
218 hospitalization in Intensive Care Unit compared to subjects aged 0-39 years. Equivalent results were
219 found for the vaccination status of the subjects: subjects with ineffective dose (adjusted OR: 3.68;
220 95% CI: 1.23 - 11.02, p value <0.001) and subjects no-vaccination (adjusted OR: 7.14; 95% CI:
221 2.64 - 19.27, p value <0.001) were at three- and seven-times higher risk of hospitalisation in
222 Intensive Care Unit, respectively, than subjects with an effective dose.

223 In Campania region, from 8 March 2021 to 31 October 2021, 3.699.683 subjects received a
224 complete vaccine schedule. Of all those vaccinated with effective dose 12,486 developed COVID-
225 19, so the prevalence of COVID-19 positive vaccinated subjects was 0.33%.

226 Regarding 12,486 subjects with an effective dose of vaccine, the ability of the vaccine to protect
227 against infection in the months following vaccination has been investigated through the
228 estimation of breakpoints, i.e., points in which data show deviations from stability in the
229 background trend. Indeed, figure 2 shows the trend for the percentage of subjects testing positive
230 for COVID-19 over the 9 months after an effective dose. Two breakpoints were identified from the
231 analysis. The first breakpoints is evident five months after vaccination ($\beta = 1.441$, $p < 0.001$). This
232 increase was most evident after the seventh month after vaccination ($\beta = 3.110$, $p < 0.001$).

233 The analysis stratified by age group showed a similar trend in subjects aged 0-39 years, 40-59 years
234 and 60-79 years in terms of increased number of COVID-19 positive patients (about 50%) up to the
235 sixth month after vaccination. On the contrary, among subjects aged over 80 years, the trend up to
236 the sixth month after vaccination was different: the percentage of positive subjects did not exceed
237 40%.

238 On the other hand, six months after vaccination, the trend was similar in all age groups (figure 3).

239 The analysis stratified by vaccine type, however, showed that all subjects vaccinated with
240 Ad26.COVS Adenoviral (J&J) (n=357) were positive for COVID-19 within one month after the
241 effective dose (third month).

242 On the other hand, 50% of the subjects vaccinated with ChAdOx1 nCoV-19 adenoviral
243 (AstraZeneca) (n=1,964) became positive from the fourth month after vaccination until they were
244 all positive by the sixth month after vaccination. 50% of the subjects vaccinated with CX-024414
245 mRNA (Moderna) (n=785) became positive from the fourth month after vaccination, between the
246 fourth and sixth month the trend remained constant, and then increased to 90% in the eighth month
247 after vaccination.

248 37% of the subjects vaccinated BNT162b2 mRNA vaccine (Pfizer-BioNTech) (n=9,237) became
249 positive from the fourth month after vaccination, between the fourth and fifth month the trend
250 remained constant, and then increased to 67% in the eighth month after vaccination.

251 **Discussion and Conclusion**

252 Vaccines have been a really successful technology for controlling infectious diseases in the past.
253 COVID19 represented a never experienced global emergency with world wide spread and high
254 mortality rate and therefore vaccines have represented a possible solution to stop SARS-CoV-2
255 spreading. Indeed, since the early phase of vaccine campaign the COVID19 contagiousness have
256 registered a decrease⁵, however few real-world studies are available on prolonged follow-up and on
257 larger cohort population. As first consideration, according to our primary outcome, the results of
258 this large community study based on Campania Region population (ISTAT censed citizens at
259 December 2020 of 5.889.567) showed that vaccination with two doses of BNT162b2 or ChAdOx1
260 still significantly reduces the risk of new PCR-positive SARS-CoV-2 infection.


261 Further it is interestingly to emphasize that they also showed a strongly significant reduction of ICU
262 hospital stay when vaccinated patients are hospitalized compared to unvaccinated subjects (Table
263 2). However, despite these findings, we found a rate of breakthrough infection of (7.3%) among
264 studied population receiving an effective vaccination schedule while 0.33% of total vaccinated
265 population in Campania Region. These showed increasing spread of positive RT-PCR according to
266 time elapsed from second dose vaccination with highest risk after five months while only after two
267 months for a single shot vaccine. The highest percentage of infected positive subjects were
268 asymptomatic while the dynamic of protection varied by vaccine type, with initially similar
269 effectiveness of both mRNA vaccines and ChAdOx1, that after 4 months become less effective
270 with a more rapid declining of coverage for adenoviral vector-based vaccine.

271 Concerning Ad26.CO2-S vaccine it seems to show a waning of adequate coverage after one
272 month after completing vaccination schedule. Those findings, however, demonstrated that vaccines
273 are able to decrease severity of SARS-CoV-2 disease once infected. Nonetheless, it seems also clear
274 that vaccine, even if effective to decrease severity of disease and risk of severe hospitalization,
275 showed a decrease in their efficacy to protect against SARS-CoV-2 contagiousness throughout the
276 time in a significant percentage but not the majority of vaccinated people. This consideration would
277 suggest that at least in some cases, the vaccine protected against symptomatic disease but not
278 against infection throughout the time. The possible reasons of our findings could be viral and
279 immune related. In fact it is to underline that according to data available for Italian National
280 Institute of Health, in Italy and therefore in Campania we have had an increase in frequency of
281 Delta variant reaching at the end of July almost 95% of all isolated virus¹⁶. Thus a less effective
282 vaccine coverage when delta variant become dominant while vaccine campaign proceed could have
283 had a role in this breakthrough. Another explanation could be in different effects of vaccination on
284 immunity, cellular or humoral possibly determining different infective state¹⁷ mainly characterized

285 by asymptomatic subjects. These considerations would also underline the need to better understand
286 what kind of impact asymptomatic infected vaccinated people may have on SARS-CoV-2 spreading
287 among unvaccinated and vaccinated people too. Indeed, even if the current findings of vaccine
288 effectiveness to protect against severe outcomes would seem to suggest that virus transmission and
289 nasopharyngeal viral presence may have limited consequences, we could have some important
290 consequences over time. In fact, in absence of an universal vaccination possible environments
291 where the SARS-CoV-2 may develop elusive strategies by increasing its mutational rate or fitness
292 could compromise vaccine efficacy. The latter event could make herd immunity less likely with
293 possible severe evolution in particular settings of patients. Despite this could be possible future
294 scenario, our findings may be of usefulness in preventing it. Particularly our study has two main
295 strengths. First, we provide extensive documentation on a large cohort of breakthrough infections,
296 based on a Regional Big Data where all COVID19 positive data are automatically evaluated,
297 matched and analysed for their vaccine status by real time ML algorithm, minimizing error on
298 records giving a real time scenario and trend. Second, this cohort is one of the largest presented in
299 literature and represents all ages underwent vaccination with a very good representation of all
300 currently approved vaccines. Therefore, in conclusion, in this study we found that although the
301 current approved COVID19 vaccine are extremely effective in reducing hospitalization and
302 particularly ICU, breakthrough infections occur with a breakpoint between 5th and 7th month after
303 vaccination and they may carry a potential infectiveness. This event could represent a challenge,
304 since such infections are often asymptomatic and may pose a risk to vulnerable populations.
305 Consequently, a boost dose could be a possible strategy while awaiting the antiviral^{18, 19} that could
306 give us a final weapon against SARS-CoV-2. However, considering highest percentage of
307 asymptomatic patients and that few data about their capacity to transmit SARS-CoV-2, further
308 screening, quarantine procedure and other preventing strategies should be guaranteed in all
309 vaccinated subjects. Finally, a surveillance approach based on the use of integrated BIG Data
310 system to match all clinical conditions too, offer a precise and real analysis with low incidence of
311 errors in the categorization of subjects.

312

313 **Figure 1.** Flowchart: cohort selection



314

*Effective dose: two vaccine doses plus 15 days (ChAdOx1-S AstraZeneca, CX-024414 Moderna, BNT162b2 BioNTech/Pfizer); one vaccine dose plus 60 days (Ad26.COV2-S J&J)

315 **Table 1.** General characteristics of COVID-19 positive patients

	Total N (%)	No	Vaccination N (%)		Effective dose*
			Ineffective dose		
			1 st dose	2 nd doses	
	171,921 (100)	146,529 (85.2)	10,772 (6.3)	2,134 (1.2)	12,486 (7.3)
Gender					
Male	83,924 (48.8)	71,693 (85.4)	5,249 (6.3)	1,168 (1.4)	5,814 (6.9)
Female	87,997 (51.2)	74,836 (85.0)	5,523 (6.3)	966 (1.1)	6,672 (7.6)
Age Groups					
0 - 39 years	87,464 (50.9)	79,686 (91.1)	3,101 (3.5)	1,099 (1.3)	3,578 (4.1)
40 - 59 years	50,539 (29.4)	42,042 (83.2)	3,419 (6.8)	462 (0.9)	4,616 (9.1)
60 - 79 years	28,079 (16.3)	21,331 (76.0)	3,371 (12.0)	372 (1.3)	3,005 (10.7)
≥ 80 years	5,839 (3.4)	3,470 (59.4)	881 (15.1)	201 (3.4)	1,287 (22.0)
Vaccine type					
ChAdOx1-S (AstraZeneca)	6,067 (3.5)	-	3,913 (64.5)	190 (3.1)	1,964 (32.4)
Ad26.COV2-S (J&J)	1,181 (0.7)	-	824 (69.8)	-	357 (30.2)
CX-024414 (Moderna)	1,774 (1.0)	-	898 (50.6)	91 (5.1)	785 (44.3)
BNT162b2 (Pfizer-BioNTech)	15,657 (9.1)	-	5,422 (34.6)	998 (6.4)	9,237 (59.0)
Disease Symptoms					
Asymptomatic	112,251 (65.3)	95,482 (85.1)	7,343 (6.5)	1,526 (1.4)	7,900 (7.0)
Paucysintomatic	14,339 (8.3)	12,542 (87.5)	865 (6.0)	134 (0.9)	798 (5.6)
Mild	10,673 (6.2)	9,368 (87.8)	599 (5.6)	60 (0.6)	646 (6.1)
Severe	482 (0.3)	431 (89.4)	35 (7.3)	1 (0.2)	15 (3.1)
Critical	57 (0.03)	47 (82.5)	6 (10.5)	-	4 (7.0)
Not available	34,119 (19.8)	28,659 (84.0)	1,924 (5.6)	413 (1.2)	3,123 (9.2)
Hospitalisation					
Yes	4705 (2.7)	3,939 (83.7)	431 (9.2)	52 (1.1)	283 (6.0)
No	167,216 (97.3)	142,590 (85.3)	10,341 (6.2)	2,082 (1.2)	12,203 (7.3)
Intensive Care Unit (ICU)					
Yes	211 (0.1)	191 (90.5)	16 (7.6)	-	4 (1.9)
No	171,710 (99.9)	146,338 (85.2)	10,756 (6.3)	2,134 (1.2)	12,482 (7.3)

*Effective dose: two vaccine doses plus 15 days (ChAdOx1-S, CX-024414, BNT162b2); one vaccine dose plus 60 days (Ad26.COV2-S)

#Vaccine type: only for subjects who have received at least one dose of vaccine


316
317

318 **Table 2.** Univariate and multivariate logistics regression of the risk of hospitalisation in Intensive Care Unit (ICU) to
319 COVID-19

	Unadjusted OR (95% CI)	p-Value	Adjusted OR (95% CI)	p-Value
Gender				
Male (<i>vs Female</i>)	1.59 (1.20 - 2.09)	0.001*	1.70 (1.29 - 2.24)	<0.001*
Age groups				
40 - 59 years (<i>vs 0-39 years</i>)	5.57 (3.05 - 10.14)	<0.001*	5.99 (3.28 - 10.90)	<0.001*
60 - 79 years (<i>vs 0-39 years</i>)	29.73 (17.13 - 51.57)	<0.001*	33.53 (19.31 - 58.23)	<0.001*
≥ 80 years (<i>vs 0-39 years</i>)	20.39 (10.21 - 40.69)	<0.001*	29.04 (14.48 - 58.27)	<0.001*
Vaccination				
Ineffective dose (<i>vs Effective dose</i>)	3.94 (1.31 - 11.79)	0.014*	3.68 (1.23 - 11.02)	0.020*
No-vaccination (<i>vs Effective dose</i>)	4.11 (1.52 - 11.06)	0.005*	7.14 (2.64 - 19.27)	<0.001*


320 **Abbreviations:** CI, confidence interval; OR, odds ratio
321 **p-value* <0.05 was considered to be statistically significant.

322 **Figure 2.** Segmented linear regression models




323

324 **Figure 3.** Percentage of COVID-19 positive patients stratified by number of months after vaccination with effective
325 dose and stratified by age groups



326

327 **Figure 4.** Percentage of COVID-19 positive patients stratified by number of months after vaccination with effective
328 dose and stratified by age groups and stratified by vaccine type



329
330

331 **References**

- 332 1. WHO Coronavirus (COVID-19) Dashboard. <https://covid19.who.int/> Accessed on 1 November
333 2021
- 334 2. Krammer F. SARS-CoV-2 vaccines in development. *Nature*. 2020 Oct;586(7830):516-527. doi:
335 10.1038/s41586-020-2798-3. Epub 2020 Sep 23.
- 336 3. Optimising the COVID-19 vaccination programme for maximum short-term impact.
337 [https://www.gov.uk/government/publications/prioritising-the-first-covid-19-vaccine-dose-jcvi-](https://www.gov.uk/government/publications/prioritising-the-first-covid-19-vaccine-dose-jcvi-statement/optimising-the-covid-19-vaccination-programme-for-maximum-short-term-impact)
338 [statement/optimising-the-covid-19-vaccination-programme-for-maximum-short-term-impact](https://www.gov.uk/government/publications/prioritising-the-first-covid-19-vaccine-dose-jcvi-statement/optimising-the-covid-19-vaccination-programme-for-maximum-short-term-impact)
339 Accessed on 1 November 2021
- 340 4. Mallapaty S. Can COVID vaccines stop transmission? Scientists race to find answers. *Nature*.
341 2021 Feb 19. doi: 10.1038/d41586-021-00450-z. Epub ahead of print.
- 342 5. Impatto della vaccinazione COVID-19 sul rischio di infezione da SARS-CoV-2 e successivo
343 ricovero e decesso in Italia [https://www.epicentro.iss.it/vaccini/pdf/report-valutazione-impatto-](https://www.epicentro.iss.it/vaccini/pdf/report-valutazione-impatto-vaccinazione-covid-19-15-mag-2021.pdf)
344 [vaccinazione-covid-19-15-mag-2021.pdf](https://www.epicentro.iss.it/vaccini/pdf/report-valutazione-impatto-vaccinazione-covid-19-15-mag-2021.pdf) Accessed on 1 November 2021
- 345 6. Bergwerk M, Gonen T, Lustig Y, Amit S, Lipsitch M, Cohen C, Mandelboim M, Levin EG,
346 Rubin C, Indenbaum V, Tal I, Zavitan M, Zuckerman N, Bar-Chaim A, Kreiss Y, Regev-Yochay
347 G. Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. *N Engl J Med*. 2021
348 Oct 14;385(16):1474-1484. doi: 10.1056/NEJMoa2109072. Epub 2021 Jul 28
- 349 7. Khoury J, Najjar-Debbiny R, Hanna A, Jabbour A, Abu Ahmad Y, Saffuri A, Abu-Sinni M,
350 Shkeiri R, Elemy A, Hakim F. COVID-19 vaccine - Long term immune decline and
351 breakthrough infections. *Vaccine*. 2021 Nov 26;39(48):6984-6989. doi:
352 10.1016/j.vaccine.2021.10.038. Epub 2021 Oct 30.
- 353 8. Pouwels KB, Pritchard E, Matthews PC, Stoesser N, Eyre DW, Vihta KD, House T, Hay J, Bell
354 JI, Newton JN, Farrar J, Crook D, Cook D, Rourke E, Studley R, Peto TEA, Diamond I, Walker
355 AS. Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2
356 infections in the UK. *Nat Med*. 2021 Oct 14. doi: 10.1038/s41591-021-01548-7. Epub ahead of
357 print.
- 358 9. Perrella A, Orlando V, Trama U, Bernardi FF, Menditto E, Coscioni E. Pre-Exposure
359 Prophylaxis with Hydroxychloroquine Does Not Prevent COVID-19 nor Virus Related Venous
360 Thromboembolism. *Viruses*. 2021 Oct 13;13(10):2052. doi: 10.3390/v13102052.
- 361 10. Orlando V, Coscioni E, Guarino I, Mucherino S, Perrella A, Trama U, Limongelli G, Menditto
362 E. Drug-utilisation profiles and COVID-19. *Sci Rep*. 2021 Apr 26;11(1):8913. doi:
363 10.1038/s41598-021-88398-y.
- 364 11. Orlando V, Rea F, Savaré L, Guarino I, Mucherino S, Perrella A, Trama U, Coscioni E,
365 Menditto E, Corrao G. Development and validation of a clinical risk score to predict the risk of
366 SARS-CoV-2 infection from administrative data: A population-based cohort study from Italy.
367 *PLoS One*. 2021 Jan 20;16(1):e0237202. doi: 10.1371/journal.pone.0237202.
- 368 12. Bliet-Bueno K, Mucherino S, Poblador-Plou B, González-Rubio F, Aza-Pascual-Salcedo M,
369 Orlando V, (...) Gimeno-Miguel A. Baseline Drug Treatments as Indicators of Increased Risk of
370 COVID-19 Mortality in Spain and Italy. *Int. J Environ Res Public Health*. 2021 Nov
371 10;18(22):11786. doi: 10.3390/ijerph182211786

- 372 13. Perrella A, Carannante N, Berretta M, Rinaldi M, Maturo N, Rinaldi L. Novel Coronavirus 2019
373 (Sars-CoV2): a global emergency that needs new approaches? *Eur Rev Med Pharmacol Sci.*
374 2020 Feb;24(4):2162-2164.
375
- 376 14. Rhee C, Kanjilal S, Baker M, Klompas M. Duration of Severe Acute Respiratory Syndrome
377 Coronavirus 2 (SARS-CoV-2) Infectivity: When Is It Safe to Discontinue Isolation? *Clin Infect*
378 *Dis.* 2021 Apr 26;72(8):1467-1474. doi: 10.1093/cid/ciaa1249.
- 379 15. Perrella A, Brita M, Coletta F, Cotena S, De Marco G, Longobardi A, Sala C, Sannino D,
380 Tomasello A, Perrella M, Russo G, Tarsitano M, Chetta M, Della Monica M, Orlando V,
381 Coscioni E, Villani R. SARS-CoV-2 in Urine May Predict a Severe Evolution of COVID-19. *J*
382 *Clin Med.* 2021 Sep 8;10(18):4061. doi: 10.3390/jcm10184061.
- 383 16. https://www.iss.it/cov19-cosa-fa-iss-varianti/asset_publisher/yJS4xO2fauqM/content/id/5807918
384
- 385 17. Wei J, Stoesser N, Matthews PC, Ayoubkhani D, Studley R, Bell I, Bell JI, Newton JN, Farrar J,
386 Diamond I, Rourke E, Howarth A, Marsden BD, Hoosdally S, Jones EY, Stuart DI, Crook DW,
387 Peto TEA, Pouwels KB, Eyre DW, Walker AS; COVID-19 Infection Survey team. Antibody
388 responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United
389 Kingdom. *Nat Microbiol.* 2021 Sep;6(9):1140-1149. doi: 10.1038/s41564-021-00947-3. Epub
390 2021 Jul 21.
- 391 18. Fischer W, Eron JJ, Holman W, Cohen MS, Fang L, Szewczyk LJ, Sheahan TP, Baric R, Mollan
392 KR, Wolfe CR, Duke ER, Azizad MM, Borroto-Esoda K, Wohl DA, Loftis AJ, Alabanza P,
393 Lipansky F, Painter WP. Molnupiravir, an Oral Antiviral Treatment for COVID-19. *medRxiv*
394 [Preprint]. 2021 Jun 17:2021.06.17.21258639. doi: 10.1101/2021.06.17.21258639.
- 395 19. Salasc F, Lahlali T, Laurent E, Rosa-Calatrava M, Pizzorno A. Treatments for COVID-19:
396 Lessons from 2020 and new therapeutic options [published online ahead of print, 2021 Nov 18].
397 *Curr Opin Pharmacol.* 2021;doi:10.1016/j.coph.2021.11.002)